Partner
Ryan's practice covers a range of technologies, including pharmaceuticals, biotechnology, immunotherapy, medical devices, computer software, business methods, vending technologies, and mechanical systems.
Prior to joining Finnegan, Ryan conducted doctoral and undergraduate research in cellular and molecular biology and biomedical engineering. His research, including work at the National Institutes of Health (NIH) and the Marine Biological Laboratory at Woods Hole, focused on advanced microscopy techniques and molecular mechanisms regulating cell division. Ryan previously served as an adjunct professor at George Washington University Law School in the Scholarly Writing Program, where he supervised student members of the Federal Circuit Bar Journal. He has participated as a panel advisor during the Pitch Rounds competition of the Southeast BIO (SEBIO) Annual Life Sciences Venture Capital Conference. Ryan also served as an advisor to the Southeast Life Sciences (SLSA) ADVANSE Virtual Pitch Rounds competition which featured early-stage life sciences companies developing solutions related to COVID-19.
Ryan has successfully represented, including as lead counsel, over a dozen disabled veterans before the U.S. Court of Appeals for Veterans Claims. He also serves as a member of the Friends Board of the Legal Services of Northern Virginia.
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
Represented Eli Lilly in patent litigations involving antibody therapies.
1:18-cv-12029, D. Mass., Judge Burroughs
1:21-cv-01015, D. Del., Judges Hall, Williams
1:18-cv-00664, D. Del., Judge Andrews
1:17-cv-00414, D. Del., Judges Goldberg, Thynge
1:15-cv-01000, D. Del., Judge Andrews
2:19-cv-00209; 2:20-cv-00070, E.D. Tex., Judge Gilstrap
1:19-cv-01539, D. Del., Judge Stark
1:13-cv-00707, S.D. Ohio, Judge Dlott
Represented Eli Lilly in a district court contempt proceeding enforcing a permanent injunction covering its Zyprexa® drug product.
1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa
3:21-cv-16766, D.N.J., Judges Kirsch, Singh
Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc.
1:21-cv-01015, D. Del., Judges Hall, Williams
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Represented Eli Lilly in patent litigations involving antibody therapies.
1:18-cv-12029, D. Mass., Judge Burroughs
AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc.
Representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the diabetes drug Farxiga®.
1:18-cv-00664, D. Del., Judge Andrews
Shire ViroPharma Inc. v. CSL Behring LLC
1:17-cv-00414, D. Del., Judges Goldberg, Thynge
AstraZeneca LP v. SigmaPharm Laboratories
Representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.
1:15-cv-01000, D. Del., Judge Andrews
Articles
Southeast Litigation Update: March and April 2024 Southeast Litigation Update: March and April 2024
July 1, 2024
IP Health Blog
Smart Baby Monitors May Be Considered Medical Devices by FDA Smart Baby Monitors May Be Considered Medical Devices by FDA
June 16, 2022
Award/Ranking
Finnegan Shortlisted for 14 LMG Life Sciences 2024 Americas Awards Finnegan Shortlisted for 14 LMG Life Sciences 2024 Americas Awards
July 18, 2024
LMG Life SciencesMedia Mention
Litigators of the Week: Shout Out Litigators of the Week: Shout Out
October 22, 2021
The AmLaw Litigation DailyPress Release
Twenty Finnegan Attorneys Recognized by Best Lawyers Twenty Finnegan Attorneys Recognized by Best Lawyers
August 20, 2021
U.S. News—Best LawyersPress Release
Finnegan Elevates Six Attorneys to Partner Finnegan Elevates Six Attorneys to Partner
January 4, 2021
Announcement
Best Lawyers Recognizes 21 Finnegan Attorneys Best Lawyers Recognizes 21 Finnegan Attorneys
August 28, 2020
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.